Z. Nikolova et al., Prevention of graft vessel disease by combined FTY720/cyclosporine A treatment in a rat carotid artery transplantation model, TRANSPLANT, 69(12), 2000, pp. 2525-2530
Background. Graft vessel disease (GVD) is an important problem often respon
sible for late graft loss. The effects of FTY720, an immunomodulator with a
novel mechanism of action were investigated in combination with cyclospori
ne A (CsA) in a carotid artery allograft model.
Methods, A segment of the carotid artery of Lewis rats was replaced by a DA
allograft, Seven groups of eight rats were treated for 8 weeks with vehicl
e (P), CsA 0.3 (C0.3), 1 (C1) or 3 (C3) mg.kg(-1).day(-1) or a combination
of CsA 1 with FTY 0.01 (C1F0.01), 0.03 (C1F0.03), and 0.1 (C1F0.1) mg.kg(-1
).day(-1). Lumen area was estimated by magnetic resonance imaging, peripher
al lymphocyte count and drug concentrations were determined at 1 and 8 week
s. Neointima, media, and lumen area were measured morphometrically. Intimal
and adventitial infiltration of mononuclear cells, and medial smooth muscl
e cells number was assessed using a score.
Results. FTY720 did not influence CsA blood concentrations. FTY720 but not
CsA decreased the PLC dose dependently. Magnetic resonance imaging revealed
that treatment groups have larger lumen size than group P. Histological an
d morphometric evaluation showed that all aspects of GVD were dose dependen
tly suppressed by treatment and lumen narrowing was prevented.
Conclusions. CsA, at clinically relevant blood levels, suppressed GVD only
partly. The addition of FTY720 was well tolerated and completely suppressed
GVD development. In vivo lumen size did not correlate with the histologica
lly estimated neointimal thickness.